APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics Reports Second Quarter 2022 Financial Results

12 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

28 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

22 Jun 2022 22:12:40 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

22 Jun 2022 16:10:00 By Nasdaq GlobeNewswire

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Global Healthcare Conference

19 May 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2022 Financial Results

12 May 2022 06:59:25 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

05 May 2022 07:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

04 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

16 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

10 Mar 2022 07:30:01 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

01 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Applied Therapeutics Supports 15th Annual Rare Disease Day

28 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

16 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

18 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

25 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

18 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids

09 Sep 2021 07:00:01 By Nasdaq GlobeNewswire